Gynecological Oncology: Personalized Diagnosis and Therapy

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 25 August 2025 | Viewed by 1302

Special Issue Editors


E-Mail Website
Guest Editor
Department of Gynaecological Oncology, Queen Elizabeth Hospital, Gateshead NE9 6SX, UK
Interests: gynecologic oncology; uterine cervical neoplasms; endometrial neoplasms

E-Mail Website
Guest Editor
Northern Gynaecological Oncology Cenrte, Queen Elizabeth Hospital, Gateshead NE9 6SX, UK
Interests: gynaecological oncology

Special Issue Information

Dear Colleagues,

The treatment of gynaecological cancers has, in recent years, seen a transformation away from universal radical extirpative surgery, non-conformal radiotherapy techniques, and a default reliance on platinum-based chemotherapy agents to a wide range of precision medical and surgical interventions, individually targeting both the patient and their cancer. Individualised treatment decisions are as important in cancer prophylaxis and detection as they are in targeting treatment based on patient preference and tumour characteristics.

From vaccination and screening for cervical dysplasia and cancer through HPV DNA and RNA techniques to informing drug therapies and prophylactic surgery in endometrial cancer and ovarian cancer, genomic medicine is driving the personalisation of targeted cancer prevention and treatments. For those with advanced cancer, stratification into prehabilitation programmes prior to treatments is helping to ensure robust patient selection for the most radical or toxic of therapies.

In an effort to provide quality precision treatments in gynaecological cancer, innovation and challenges have been critical to informing larger-scale evidence. This Special Issue welcomes submissions that contain original research in the translational and clinical domains or review articles that demonstrate innovation towards the personalisation of gynaecological cancer detection, prevention, and treatment across surgical, radiation, and medical oncology fields and palliative medicine.

Dr. Stuart Rundle
Dr. Ali Kucukmetin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynaecologic oncology
  • surgical oncology
  • medical oncology
  • radiation oncology
  • clinical oncology
  • palliative medicine
  • diagnosis
  • translational research
  • stratification
  • patient selection
  • genomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 363 KiB  
Article
Trachelectomy and Cerclage Placement as Fertility-Sparing Surgery for Cervical Cancer—An Expert Survey
by Anke Smits, Janneke T. Wolswinkel, Mieke L. G. ten Eikelder, Nadeem R. Abu-Rustum, Glauco Baiocchi, Jogchum J. Beltman, Allan Covens, Karlijn M. C. Cornel, Henrik Falconer, Christina Fotopoulou, Cornelis G. Gerestein, Blanca Gil-Ibanez, Peter Hillemanns, Christhardt Köhler, Ali Kucukmetin, Luc R. C. W. van Lonkhuijzen, Philippe Morice, Joo Hyun Nam, Myriam B. Perrotta, Jan Persson, Marie Plante, Denis Querleu, Reitan Ribeiro, Laszlo Ungár, Maaike A. P. C. van Ham and Petra L. M. Zusterzeeladd Show full author list remove Hide full author list
J. Pers. Med. 2025, 15(3), 77; https://doi.org/10.3390/jpm15030077 - 20 Feb 2025
Viewed by 862
Abstract
Background/Objectives: Fertility-sparing surgery (FSS) is a standard practice for managing early stage cervical cancer, yet significant variation exists in clinical approaches worldwide. Our objective was to ascertain current practices and preferences for cerclage use among expert centers globally regarding FSS in patients [...] Read more.
Background/Objectives: Fertility-sparing surgery (FSS) is a standard practice for managing early stage cervical cancer, yet significant variation exists in clinical approaches worldwide. Our objective was to ascertain current practices and preferences for cerclage use among expert centers globally regarding FSS in patients with early stage cervical cancer. Methods: We conducted a cross-sectional survey from May to July 2023 involving expert centers identified through their scientific contributions and participation in international workgroups and conferences.. The survey, comprising 27 questions, evaluated existing practices in FSS. Results: Out of the centers surveyed, 21 (36.2%) gynecologic oncologists responded. For tumors <2 cm, 86% of centers preferred radical trachelectomy, primarily via the vaginal approach, while 13.6% favored a simple trachelectomy. Three experts preferred simple trachelectomy (13.6%). For tumors >2 cm, 47.6% utilized neoadjuvant chemotherapy before trachelectomy. Others did not offer FSS or performed an abdominal radical trachelectomy. Over time, there has been a shift towards less radical surgeries for tumors <2 cm and increased use of neoadjuvant chemotherapy for larger tumors. Some abandoned the minimally invasive surgical approach. Nearly all experts (90.5%) placed a cerclage immediately following trachelectomy. Conclusions: The majority of experts opt for radical trachelectomy in early stage cervical cancer, with immediate cerclage placement being a common practice. However, considerable international variations highlight the urgent need for standardized guidelines and further research to optimize treatment strategies, balancing oncological safety with fertility outcomes. Full article
(This article belongs to the Special Issue Gynecological Oncology: Personalized Diagnosis and Therapy)
Show Figures

Figure 1

Back to TopTop